NCT03320811

Interpretation of Serological Tests in the Diagnosis of Celiac Disease: Anti-deamidated Gliadin Peptide Antibodies Revisited

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,026 (actual)
• Sponsor: CHU de Reims · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Celiac disease is an autoimmune disorder characterized by a chronic inflammation of the small bowel mucosa, triggered by the ingestion of gluten-containing grains. The diagnosis of celiac disease was initially based on duodenal biopsies obtained from upper endoscopy. Since 1990, the availability of serological tests has contributed to a different perception of the disease. Serological testing is now considered fundamental for celiac disease screening, even if duodenal biopsies remain the gold standard. Celiac markers usually include anti-TG2 antibodies, anti-endomysium antibodies, anti-gliadin antibodies and anti-reticulin antibodies. Recently, several studies showed that deamidated products of gliadin may enhance T-cell stimulatory activity and improve the reactivity of anti-gliadin antibodies. Thus, detection of anti-deamidated gliadin peptide antibodies has been introduced into the wide spectrum of serological tests for celiac disease.

Detailed description

The aim was to assess the clinical relevance of anti-deamidated gliadin peptide antibodies compared with the other common celiac markers.

Conditions

• Celiac Disease

Interventions

Type	Name	Description
OTHER	Data record

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-09-01
• Completion: 2016-01-01
• First posted: 2017-10-25
• Last updated: 2017-10-25

Locations

1 site across 1 country: France